To test the hypothesis that glucocorticoid-induced insulin resistance might originate from abnormalities in insulin receptor signaling, we investigated the effects of glucocorticoids on in vivo tyrosine phosphorylation of the insulin receptor and the insulin receptor substrate IRS-1 in rat skeletal muscle. Male Sprague-Dawley rats were treated with cortisone (100 mg/kg for 5 d) and compared to pair-fed controls. Cortisone treatment of rats resulted in both hyperglycemia and hyperinsulinemia. Anesthetized animals were injected with 10 U/kg insulin via cardiac puncture and, after 2 min, hindlimb muscles were removed, snap-frozen, and homogenized in SDS. Protein tyrosine phosphorylation was studied by immunoblotting with phosphotyrosine antibody. Insulin receptors and substrate IRS-1 were identified and quantified with specific antibodies. Cortisone treatment increased the amount of insulin receptor protein by 36%, but decreased the total level of receptor tyrosine phosphorylation (69 +/-4% of control, P < 0.05). The decreased level of receptor phosphorylation was explained by a reduced number of receptors containing phosphorylated tyrosine residues (64.6 +/-5% of control, P < 0.05). Glucocorticoid excess decreased skeletal muscle IRS-1 content by 50%, but did not significantly alter the total level of IRS-1 tyrosine phosphorylation. The apparent M(r) of IRS-1 was reduced by approximately 10 kD. Treatment with protein phosphatase-2A reduced IRS-1 M(r) in control but not in glucocorticoid-treated muscle indicating that the lower M(r) likely […] 
Introduction
To test the hypothesis that glucocorticoid-induced insulin resistance might originate from abnormalities in insulin receptor signaling, we investigated the effects of glucocorticoids on in vivo tyrosine phosphorylation of the insulin receptor and the insulin receptor substrate IRS-1 in rat skeletal muscle. Male Sprague-Dawley rats were treated with cortisone (100 mg/kg for 5 d) and compared to pair-fed controls. Cortisone treatment of rats resulted in both hyperglycemia and hyperinsulinemia. Anesthetized animals were injected with 10 U/kg insulin via cardiac puncture and, after 2 min, hindlimb muscles were removed, snap-frozen, and homogenized in SDS. Protein tyrosine phosphorylation was studied by immunoblotting with phosphotyrosine antibody. Insulin receptors and substrate IRS-1 were identified and quantified with specific antibodies. Cortisone treatment increased the amount of insulin receptor protein by 36%, but decreased the total level of receptor tyrosine phosphorylation (69±4% of control, P < 0.05). The decreased level of receptor phosphorylation was explained by a reduced number of receptors containing phosphorylated tyrosine residues (64.6±5% of control, P< 0.05). Glucocorticoid excess decreased skeletal muscle IRS-1 content by 50%, but did not significantly alter the total level of IRS-1 tyrosine phosphorylation. The apparent M, of IRS-1 was reduced by 10 kD.
Treatment with protein phosphatase-2A reduced IRS-1 Mr in control but not in glucocorticoid-treated muscle indicating that the lower M, likely results from lower phosphoserine and/or phosphothreonine content. To investigate the role of hyperinsulinemia in the glucocorticoid response, rats were made insulin-deficient with streptozotocin (100 mg/kg, i.p.). Subsequent treatment with cortisone for 5 d had no effects on insulin levels, tyrosine phosphorylation of insulin receptors or IRS-1, or the Mr of IRS-1. In conclusion, glucocorticoid-treated skeletal muscle is characterized by: (a) decreased total tyrosine phosphorylation of insulin receptors as a result of a reduction in the pool of receptors undergoing tyrosine phosphorylation; (b) decreased IRS-1 content and reduced serine and/or threonine phosphorylation of IRS-1. Glucocorticoid-induced hyperinsulinemia appears to be essential for the development of these alterations. (J. Clin. Invest. 1993. 91:2020-2030.) Key words: autophosphorylation -cortisone * insulin receptor substrate-i.
insulin resistance * tyrosine kinase activity An excess of glucocorticoid hormones, commonly observed in patients treated with these steroids or affected by Cushing's syndrome, leads to insulin resistance ( 1, 2) . In humans and in several experimental models, glucocorticoid excess has been shown to antagonize insulin action by inhibiting insulin-mediated glucose uptake and utilization by insulin-sensitive tissues (3, 4) . In skeletal muscle, the major site of insulin-mediated glucose disposal, glucocorticoid treatment results in a decreased ability of insulin to maximally stimulate glucose transport (5, 6) . Although glucocorticoid-induced insulin resistance has been recognized for over three decades, the molecular basis for the defect in insulin action has not yet been identified.
According to the current model of insulin transmembrane signaling, insulin binding to a specific tetrameric receptor located at the cell surface (7) results in receptor autophosphorylation and activates the tyrosine kinase intrinsic to the receptor's ,3 subunit (8) (9) (10) . This leads in turn to tyrosine phosphorylation of intracellular substrate proteins (11) (12) (13) (14) (15) (16) ) that may function as messengers for various biological effects of insulin. The most ubiquitous substrate for the insulin receptor kinase is a cytoplasmic phosphoprotein with M, between 160,000 and 185,000. Tyrosine phosphorylation of this protein in response to insulin stimulation is evident in the major insulin-sensitive tissues, including liver, skeletal muscle, and fat cells (17) (18) (19) . Recently, a cDNA encoding a component of the Mr 160,000-185,000 protein was sequenced, and the corresponding protein was named "IRS-I" (insulin receptor substrate-l )' ( 18, 20) . The expression and tyrosine phosphorylation of IRS-1 represent specific molecular events to investigate in the search for abnormalities in the insulin signaling pathway that may lead to insulin resistance.
The observed effects of glucocorticoids on insulin receptor content and binding activity have varied, depending on the specific glucocorticoid used, the cell type studied, and the employment of in vivo or in vitro experimental conditions (reviewed in reference 2) . A lack of correlation between changes in insulin binding activity and impairment in insulin action has lead to the conclusion that a postbinding mechanism is responsible for glucocorticoid-induced insulin resistance (21) (22) (23) . When insulin receptor tyrosine kinase activity was measured in the skeletal muscle and adipocytes of hypercortisole-phorylation was found (24, 25) . However, these prior studies evaluated insulin receptor autophosphorylation in vitro using detergent-extracted and partially purified receptors (24) , and tyrosine kinase activity was measured with exogenous or synthetic substrates (24, 25) . The effects of glucocorticoids on tyrosine phosphorylation have not been studied in vivo, and specific cellular proteins that are substrates for the insulin receptor kinase have not been investigated.
To study protein tyrosine phosphorylation in vivo, we have recently used a method (26) that involves insulin injection in intact animals, followed by rapid isolation of muscle tissue and identification of tyrosine phosphoproteins with specific antibodies. This experimental procedure makes it possible to assess the phosphorylation reactions that occur in the intact animal in response to circulating insulin and to study endogenous substrate proteins. When in vivo protein tyrosine phosphorylation was studied in streptozotocin-induced diabetic rats (26), a paradoxical increase in tyrosine phosphorylation ofboth the insulin receptor and substrate IRS-I was found, in marked contrast with other studies where tyrosine phosphorylation was evaluated in vitro (27) (28) (29) . With the assumption that this in vivo approach could reveal defects in insulin signaling that are not evident with in vitro techniques, we have investigated the effects of glucocorticoids on insulin-stimulated tyrosine phosphorylation in rat skeletal muscle. Our results indicate that glucocorticoid excess results in decreased insulin receptor tyrosine phosphorylation and changes in both the expression and the molecular structure of the substrate IRS-1.
Methods

Materials
Human insulin (Humulin R) was (31 ) . Glucocorticoid-treated animals were allowed free access to standard rat laboratory diet plus water. Because glucocorticoid treatment resulted in reduced food intake (-60% of control), treated animals were compared with pair-fed controls. The pair-fed group received an amount of food equal to the previous day's consumption in the glucocorticoid-treated group. For selected studies, rats were made diabetic and insulin-deficient by i.p. injection of STZ in citrate buffer, pH 4.5 ( 100 mg/kg body wt). Blood (32) . Circulating insulin levels were measured as described by Soeldner and Sloane (33) using rat insulin standard. Quantitation of muscle DNA was performed using the fluorimetric method described by Labarca and Paigen (34) . Procedures Preparation and purification ofantibodies. Anti-phosphotyrosine antibody (a-PY) was prepared in rabbits by injection of phosphotyrosine polymerized by l-ethyl-3(3-dimethyl-aminopropyl)carbodiimide with alanine, threonine, and KLH as previously described (26) . Nonimmunoglobulin proteins were extracted with 6% octanoic acid precipitation. Then, a-PY was purified by affinity chromatography on a phosphotyramine-Sepharose column, as previously described (35) . The final protein concentration of the antibody was 200-500 ,g/ml.
An anti-insulin receptor antibody (a-IRCt) against the synthetic peptide, Arg-Thr-Tyr-Asp-Glu-His-Ile-Pro-Tyr-Thr-His, which contains the carboxy-terminal amino acid sequence between residues 1328-1338 ofthe # subunit ofthe cloned rat insulin receptor (30) , was generated and purified by affinity chromatography on a peptide-coupled Affigel 15 column as previously described (26, 35 2 ,gg/ml a-PY in rinse buffer containing 5% BSA for 10-16 h at 4VC. After washing twice with rinse buffer plus 0.05% Nonidet P40, and once with rinse buffer plus 0.1 % Tween-20, the sheets were incubated with '25I-protein A (1 sCi/ml) for 1 h at 25°C, washed again with rinse buffer as described above, air-dried, and subjected to autoradiography with X-Omat (Eastman Kodak Co., Rochester, NY) film in the presence ofan intensifying screen at -80°C for 6-48 h. Titers of muscle proteins immunoprecipitated and then blotted with a-PY showed a linear relationship between the amount of starting protein and the density ofthe autoradiographic images. Moreover, in control experiments, the a-PY antibody was found to immunoprecipitate 90% and 80% of tyrosine phosphorylated insulin receptors and IRS-1, respectively. This was assessed by comparing the amount of tyrosine phosphorylated insulin receptors and IRS-I (measured by immunoblotting an aliquot ofthe muscle protein extracts with a-PY antibody) before and after immunoprecipitation with a-PY antibody.
To specifically identify and quantify insulin receptors and substrate IRS-1 in muscle protein extracts, parallel experiments were performed using an anti-insulin receptor antibody, a-IRCt, as previously described (26), or one ofseveral anti-IRS-I antibodies, a-IRS-1. A linear relationship between the amount of muscle protein and the density of autoradiographic images was observed for samples immunoprecipitated and then blotted with a-IRCt and a-IRS-1, similar to a-PY. Autoradiographic images were quantified by densitometry, and data were expressed using arbitrary units after normalizing to control values within each gel. 10 ,g/ml aprotinin, I mM sodium orthovanadate, and 1% Triton X-100 for 60 min at 4VC with continuous shaking. The solubilized material was then centrifuged at 100,000 g for 60 min, and the supernatant applied to a 4-ml wheat germ agglutinin agarose column preequilibrated with column buffer containing 50 mM Hepes (pH 7.6), 150 mM NaCl, 1 mM PMSF, and 0.1% Triton X-100. Glycoproteins were eluted with the same buffer containing 0. Dephosphorylation experiments. The serine-and threonine-specific protein phosphatase-2AC (PP-2AC), purified according to Usui et al. (38) by Dr. D. L. Brautigan (Providence, RI), was used to dephosphorylate serine and threonine residues of IRS-1 in vitro. Tyrosine phosphoproteins from both control and glucocorticoid-treated animals first were immunoprecipitated with a-PY antibodies and protein A-agarose beads, as described above. The immunoprecipitates were washed three times in 50 mM Hepes buffer (pH 7.6) containing 1% Triton X-100, 0.1% SDS, 100 mM sodium fluoride, and 1 mM sodium orthovanadate, and five times in 50 mM Tris buffer (pH 8.0) containing 150 mM NaCl and 1 mM PMSF. Tyrosine phosphoproteins were eluted from the beads with 100 mM HC1, neutralized to pH 7.8 and incubated with 0.007 U/,u PP-2AC in the presence of 1 mM MgCl2 and 30 mM ,Bmercaptoethanol for 1 h at 37°C. Then, the samples were boiled in Laemmli buffer containing 100 mM DTT, subjected to SDS-PAGE and immunoblotted with a-IRS-I antibody, as described above.
Statistical analysis
All data are presented as mean±SE. Statistical analyses were performed by paired and unpaired Student's t tests.
Results
Experimental animals. Table I summarizes the body weights, plasma glucose, and plasma insulin concentrations ofthe experimental animals. As expected, the cortisone treatment regimen induced a catabolic state. Rats treated with cortisone ( 100 mg/ kg, s.c.) for 5 d lost an average of 26±2 g in body weight over the 5-d study period. The pair-fed controls gained 8±2 g over the same study period and, thus, the enhanced catabolism induced by glucocorticoid treatment and not the reduced food intake was responsible for the loss in body weight. When treated with glucocorticoids, STZ-treated animals showed a significantly greater decrease in body weight (P < 0.05) compared to pair-fed STZ-controls.
Plasma glucose concentrations in glucocorticoid-treated animals measured between 9:30 and 11:00 a.m. in the non-fasted state were clearly elevated into the hyperglycemic range (Table I , group a.). In these animals, the presence of insulin resistance was confirmed by the simultaneous occurrence of markedly elevated plasma insulin concentrations. Animals treated with a single dose of STZ were also markedly hyperglycemic. Despite the presence of hyperglycemia, nonfasted plasma insulin concentrations in these STZ-treated rats were not elevated and were not changed significantly by 5 d ofcortisone treatment (Table I , group b.).
Because glucocorticoid excess is known to induce a decrease in muscle protein, we measured muscle DNA content as an index of muscle cell number. After 5 d of treatment with cortisone, the mean hindlimb muscle DNA/protein ratio was slightly higher but not significantly different from pair-fed controls (7.9±0.7 vs. 6.7±0.7 ,gg/mg muscle protein, NS).
Insulin-stimulated tyrosinephosphorylation. To investigate the effects of glucocorticoid excess on insulin-stimulated tyrosine phosphorylation, rats were studied after 5 d of cortisone treatment and compared to pair-fed controls. To maximally stimulate protein tyrosine phosphorylation in skeletal muscle, insulin was injected via cardiac puncture at the dose of 10 U/kg body weight, and hindlimb muscles were rapidly harvested after 2 min and frozen in liquid N2. This dose of insulin and the 2-min time point were chosen because a maximally effective stimulation of both insulin receptor and substrate phosphorylation is observed in control animals under these experimental conditions (26) . Muscle tissue was subsequently homogenized under highly denaturing conditions ( 1% SDS plus 50 mM DTT, at 100IC) to prevent the occurrence of phosphatase-mediated dephosphorylation (18). Tyrosine phosphoproteins were precipitated with a-PY antibody and subsequently identified with a-PY antibody and 251I-protein A on immunoblots. Equal amounts of muscle protein from control and glucocorticoid-treated animals were used for the immunoprecipitation experiments. The immunoprecipitation step was necessary both to concentrate the proteins of interest and to remove other more abundant muscle proteins (e.g., myosin) that may interfere with detection and quantitation of specific bands on immunoblots.
Insulin injection resulted in the stimulation of tyrosine phosphorylation of two major proteins with M, of 95,000
(pp95) and 170,000 (pp 170) in both control and glucocorticoid-treated animals. Fig. 1 Based on their apparent M, the tyrosine phosphoproteins pp95 and pp 170 observed in immunoblots with a-PY antibody were hypothesized to represent the insulin receptor ,B subunit and the insulin receptor substrate IRS-1, respectively. To test this hypothesis, specific antibodies to the carboxy-terminal region of the rat insulin receptor 3 subunit (a-IRCt) and the carboxy-terminal region of rat IRS-1 (a-IRS-1) were used to specifically identify the two proteins in a-PY precipitates. In the experiment shown in Fig. 2 , a-PY precipitates of muscle proteins from both control and glucocorticoid-treated animals were resolved on SDS-PAGE in triplicate and subsequently To quantitate the changes in insulin receptor and IRS-1 tyrosine phosphorylation in glucocorticoid-treated animals, autoradiographs from multiple experiments were analyzed by densitometry. As shown in Fig. 3 , there was a significant decrease in the level of insulin-stimulated insulin receptor tyrosine phosphorylation (69±4% of controls, P < 0.05) in the skeletal muscle of animals treated with cortisone for 5 d. The level oftyrosine phosphorylation ofIRS-I was not significantly altered by the glucocorticoid-treatment (88±5% of controls, NS). However, in a limited group of animals in which the glucocorticoid treatment regimen was associated with a more pronounced hyperinsulinemic response (insulin levels > 180 ,uU/ml), IRS-I tyrosine phosphorylation was modestly but significantly reduced (-25%, P < 0.05, data not shown). As shown in the inset ofFig. 3, quantitation ofIRS-1 phosphorylation relative to the degree of insulin receptor phosphorylation did not show any significant difference between glucocorticoidtreated and control animals. sine residues phosphorylated in each individual receptor molecule and/or a decrease in the population of receptors that undergo tyrosine phosphorylation. These two possibilities were investigated by measuring the total quantity ofreceptors as well as the quantity of in vivo tyrosine phosphorylated receptors in the skeletal muscle of hypercortisolemic animals compared to controls.
In immunoprecipitation experiments using muscle protein extracts from both control and glucocorticoid-treated animals, the a-PY antibody was found to precipitate -90% and 80% of the tyrosine phosphorylated insulin receptors and IRS-1 present in the extracts, respectively (data not shown). To assess whether the efficiency of precipitation by the a-PY antibody was dependent on the extent of receptor phosphorylation, we compared the ability of a-PY to immunoprecipitate partially phosphorylated and fully phosphorylated insulin receptors that were labeled with 32P and added to the muscle extracts. Insulin receptors with phenylalanine replacing tyrosine-l 146, one of the major tyrosine phosphorylation sites in the receptor # subunit, were used as a source of partially phosphorylated insulin receptors. These mutant receptors are characterized by a reduced stoichiometry of tyrosine autophosphorylation compared to wild-type receptors (37) . Mutant as well as wild-type insulin receptors were partially purified, incubated with 100 nM insulin, and autophosphorylated in vitro in the presence of
[32P]ATP. Then, they were mixed with muscle protein extracts from the experimental animals and subjected to immunoprecipitation with a-PY antibody. Greater than 95% of both the wild-type and tyrosine-l 146 mutated receptors were precipitated by the a-PY antibody. This was assessed by comparing the amount of32P-labeled receptors precipitated and remaining in the supernatants after immunoprecipitation. The autoradiograph in Fig. 4 To estimate the total quantity of insulin receptors present in the muscle protein extracts independent of phosphorylation state, the anti-insulin receptor antibody a-IRCt, generated against the carboxy-terminal amino acid sequence of the rat insulin receptor, was used as previously described (26) . Equal amounts of solubilized muscle protein from the experimental animals were subjected to immunoprecipitation with a-IRCt. Subsequently, a-IRCt precipitates were resolved by SDS-PAGE under reducing conditions and then immunoblotted with a-IRCt and '251-protein A. A representative autoradiograph of experiments performed according to this procedure is shown in Fig. 5 A. The single sharp band at M, 95,000 represents the # subunit of the insulin receptor. Quantitative analysis of multiple experiments, illustrated in Fig. 5 C, indicated that the total levels of insulin receptor protein were increased by 36% (P < 0.05) in the skeletal muscle of hypercortisolemic animals compared to controls. To determine the number of tyrosine phosphorylated receptors, experiments were conducted in parallel using muscle protein extracts from the same experimental animals. Receptors containing phosphorylated tyrosine residues were selectively immunoprecipitated with a-PY antibody, and the amount ofreceptor protein in these a-PY precipitates was then quantitated by immunoblotting with the a-IRCt antibody. A representative experiment is presented in Fig. 5 B, and the result of quantitative analysis of multiple experiments in Fig. 5 D. The quantity of tyrosine phosphorylated receptors was significantly reduced in glucocorticoidtreated animals compared to controls. Since the decrease in tyrosine phosphorylated receptors (35%) is approximately equal to the decrease in total insulin receptor tyrosine phosphorylation (36%, Fig. 3 ), we conclude that decreased insulin receptor tyrosine phosphorylation in the glucocorticoid-treated animals reflects a reduced number of receptors undergoing tyrosine phosphorylation rather than a reduced number ofphosphotyrosines per receptor molecule. To further investigate the mean stoichiometry of insulin receptor phosphorylation in vivo, we determined the ratio of tyrosine phosphorylated receptors to total receptors in each individual animal. As shown in Fig. 5 E, the ratio was markedly decreased by glucocorticoid treatment (56.7±4% of control, P < 0.05). These findings further establish the existence of an increased population of unphosphorylated insulin receptors in the skeletal muscle of animals treated with glucocorticoids.
With a similar experimental approach, the amounts oftotal as well as tyrosine phosphorylated substrate IRS-I were determined in the skeletal muscle of the experimental animals (Fig.  6 ). To measure the total amount of IRS-1, solubilized muscle proteins from glucocorticoid-treated and control animals were subjected to sequential immunoprecipitation and immunoblotting with antibody specific to rat IRS-1 (20) . The antibody preparation used for these experiments has been demonstrated to react with IRS-I independent ofthe phosphorylation state of the protein (data not shown). As evident from both the representative autoradiograph presented in Fig. 6 A, representative experiment is presented in Fig. 6 B, and the quantitative analysis in Fig. 6 D. Despite the decreased total muscle content of IRS-1, the amount of tyrosine phosphorylated IRS-I was unchanged by glucocorticoid treatment. This is consistent with the lack of change in the total amount of tyrosine phosphorylation of IRS-1, measured by a-PY antibody immunoprecipitation and blotting (Fig. 3) . Taken together, these results indicate that the total amount of IRS-1 tyrosine phosphorylation and the total pool of IRS-I molecules that undergo tyrosine phosphorylation in response to insulin stimulation in vivo are unaltered by glucocorticoid treatment. Since the total muscle content of IRS-1 is decreased by glucocorticoid treatment, however, a greater fraction of IRS-I must be tyrosine phosphorylated in glucocorticoid-treated animals. This is illustrated in Fig. 6 E, where the ratio of tyrosine phosphorylated IRS-1 to total IRS-I is illustrated. The ratio is increased approximately twofold in the skeletal muscle of hypercortisolemic animals.
Effects ofglucocorticoids on protein tyrosine phosphorylation in insulin-deficient animals. To investigate the role of hyperinsulinemia in the glucocorticoid response, animals were made insulin-deficient with STZ (100 mg/kg, i.p.) and subsequently treated with cortisone acetate (100 mg/kg, s.c.) for 5 d. Pair-fed STZ-treated animals were used as controls. Cortisone treatment of STZ-animals had no effect on insulin levels (Table I) and did not significantly alter either insulin receptor or IRS-1 tyrosine phosphorylation (84.7±4% and 111.7±11% of controls, respectively, NS) (Fig. 7, toppanel) . Also, no changes in the molecular weight of IRS-1 were observed with glucocorticoid treatment ofSTZ-rats (data not shown). Cortisone treatment of STZ-animals did not significantly alter the total quantity of insulin receptors, but significantly increased the total amount ofIRS-I in skeletal muscle ( 179±14% oflevels in STZanimals, P < 0.05) (Fig. 7, bottom panel) . The increase in the total amount of IRS-I protein after cortisone treatment ofSTZ animals is in contrast with the effects of this steroid agent on non-STZ rats (see above) and also differs from the effects of STZ-diabetes per se (39) , both of which result in a decreased amount ofIRS-1 protein in skeletal muscle. These experiments indicate that hyperinsulinemia is a necessary component for the effects ofglucocorticoids on both tyrosine phosphorylation and protein levels ofthe insulin receptor and IRS-1 in rat skeletal muscle.
Increased electrophoretic mobility of IRS-1. As noted above in the comments relating to Fig. 1 and evident also in Fig. 2 , tyrosine phosphorylated IRS-1 from glucocorticoidtreated skeletal muscle consistently migrated with increased mobility on SDS-PAGE compared to control (-160 vs. 170 kD, respectively). The IRS-1 protein from control and glucocorticoid-treated animals interacted on immunoblots with multiple antibodies directed against different domains ofthe molecule. As shown in Fig. 8 , these included antibody preparations specific to the last 14 carboxy-terminal amino acids and the first 12 amino-terminal amino acids. Tyrosine-phosphorylated IRS-1 from glucocorticoid-treated and control muscle reacted equally well with antibodies to both of these domains, indicating that the carboxy-as well as the amino-terminal regions of IRS-1 are intact in glucocorticoid-treated and control muscle.
The altered electrophoretic mobility of IRS-1 after glucocorticoid administration could result from a decrease in phosphorylation of the protein. The increased electrophoretic mobility of IRS-1 in glucocorticoid-treated animals was not associated with a change in phosphotyrosine content ofthe protein, but it could potentially be explained by reduced phosphorylation of serine and/or threonine residues. The published sequence of IRS-1 contains 35 putative serine/threonine phos- Anesthetized rats were injected with insulin ( 10 U/kg body wt) via cardiac puncture. After 2 min, hindlimb muscle was harvested and processed as described in Methods for identification of tyrosine phosphorylated proteins. Autoradiographs of a-PY immunoblots from multiple experiments were subjected to scanning densitometry, and the levels of insulin receptor and IRS-l tyrosine phosphorylation quantified. The total amounts of insulin receptors and IRS-I were quantitated with specific antibodies to these proteins as described in the Methods. Data are expressed as a percentage of values in STZ controls.
phorylation sites distributed throughout the protein (20) , and serine as well as threonine phosphorylation of IRS-1 has been shown to occur in intact cells (20) . To investigate the effects of serine/threonine dephosphorylation on the electrophoretic mobility of IRS-1, muscle protein extracts from insulin-stimulated hypercortisolemic and control animals were subjected to immunoprecipitation with a-PY antibody and then incubated with protein phosphatase-2AC (PP-2AC), a specific serine/ threonine phosphatase (38) . The protein products were resolved by SDS-PAGE, and IRS-I identified with a-IRS-I antibody on immunoblots. As shown in Fig. 9 , treatment with Figure 8 . (24) on insulin receptor tyrosine kinase activity in skeletal muscle of hypercortisolemic animals that showed normal receptor autophosphorylation and kinase activity. The differences between the two studies may be explained by the distinct experimental methods used to assess insulin receptor tyrosine kinase activity. Although insulin stimulation was performed in vivo with an intravenous injection in the study by Block and Buse (24) , receptor phosphorylation was studied in vitro in a cell-free system. In our experimental system, insulin-stimulated receptor phosphorylation occurred entirely in vivo, under conditions where the integration of receptors into muscle tissue structure was preserved. It is conceivable that the decreased fraction of tyrosine phosphorylated receptors in muscle of glucocorticoid-treated animals reflects their altered subcellular distribution and accessibility to insulin binding. On solubilization, insulin may gain access to all receptors, and the phosphorylation defect thus may no longer be evident. Our study also differs from that of Block and Buse (24) in that we used a pair-feeding protocol to assure equal food intake in control and glucocorticoid-treated animals. A decrease (-40%) in food intake occurs when high doses of glucocorticoids are administered, and this could influence protein tyrosine phosphorylation per se. It is important to consider in this regard that fasting and feeding have been shown to regulate insulin receptor phosphorylation in rat liver and muscle both in vitro (40) and in vivo (39) . Moreover, the effects of glucocorticoids on insulin receptor kinase activity have been shown to be profoundly modulated by the dietary state of the animal (41 ) .
We have presented evidence that the population of skeletal muscle insulin receptors capable of undergoing tyrosine phosphorylation in response to insulin stimulation in vivo is reduced following glucocorticoid treatment. These findings suggest the existence of two distinct population of receptors, one capable of undergoing tyrosine phosphorylation and one unable to autophosphorylate in response to insulin. The phosphorylatable pool appears to decrease and the unphosphorylatable pool to increase in association with glucocorticoid-induced insulin resistance. The existence of a pool of "kinase-silent" receptors has previously been demonstrated by Pang et al. (42) in Fao cells, where this pool appears to represent > 50% of total cellular insulin receptors. In another study, Brillon et al. (43) photoaffinity-labeled insulin receptors from normal and non-insulin-dependent diabetic subjects and then used a-PY and a-IRCt to discriminate between receptors capable of autophosphorylation in vitro and receptors that could not be phosphorylated. These authors showed that the pool of kinase-defective insulin receptors is increased in adipocytes from insulin-resistant diabetic subjects and suggested that this provides an explanation for the defect in insulin receptor kinase activity observed in these patients. They concluded that impaired tyrosine phosphorylation is an intrinsic biochemical feature ofthe subpopulation ofreceptors and suggested that the defect in receptor phosphorylation could derive from an increase in the ATP K., resulting in less phosphate transferred to the receptors, or from an increase in serine phosphorylation of the insulin receptor, which has been shown to inhibit insulinstimulated tyrosine phosphorylation of the 3 subunit (44) .
To explain the increase in the population of receptors that do not undergo tyrosine phosphorylation in response to insulin in our in vivo system, an additional mechanism can be hypothesized. While it is unlikely that decreased receptor phosphorylation reflects differences in binding affinity for insulin, since the insulin dose that we used to stimulate tyrosine phosphorylation was maximally effective for both control and hypercortisolemic animals, it is possible that a fraction of the insulin receptors are not available for insulin binding and subsequent activation because they are not at the cell surface. Animals treated with glucocorticoids were markedly hyperinsulinemic, and chronic hyperinsulinemia has been shown to induce "down-regulation" and loss of cell-surface receptors (45) . The pattern of an increased total receptor content associated with a decreased proportion of "functional" receptors in skeletal muscle could reflect the product of the in vivo interplay between glucocorticoid excess and hyperinsulinemia, whereby glucocorticoids act to increase insulin receptor expression (46) and insulin opposes this phenomenon by promoting receptor down-regulation. The importance of hyperinsulinemia for the glucocorticoid response is supported by the observation that insulin receptor phosphorylation was not decreased when the glucocorticoid excess was created in animals made insulin-deficiency by STZ administration.
Glucocorticoid excess resulted in abnormalities in the insulin signaling pathway involving post-receptor steps including the expression and in vivo phosphorylation of the substrate IRS-1. IRS-I is rapidly phosphorylated on tyrosine residues after insulin stimulation in intact cells (20) and this is thought to somehow lead to the next step(s) in insulin signaling. Sitedirected mutagenesis studies have demonstrated impaired insulin signaling by insulin receptors that undergo autophosphorylation normally but are incapable of mediating IRS-I tyrosine phosphorylation (47, 48) . Although this suggests a direct relationship between IRS-I tyrosine phosphorylation and insulin action, we have recently demonstrated increased tyrosine phosphorylation of IRS-1 in the skeletal muscle of animals made diabetic and insulin-resistant by STZ administration (26) . Similar results have been obtained in studies on liver tissue from STZ-diabetic animals (39) . Therefore, the pathophysiologic significance of the levels of tyrosine phosphorylation of IRS-I in insulin-sensitive tissues remains uncertain.
In glucocorticoid-treated, insulin-resistant animals, the skeletal muscle content of IRS-I was decreased by -50%. This response is similar to recently reported findings with 3T3-LI adipocytes, in which dexamethasone down-regulated IRS-1 content by 60% and concomitantly caused insulin resistance (49) . In spite of the decrease in IRS-I content in the current study, neither the total level of tyrosine phosphorylation of IRS-I nor the amount of tyrosine phosphorylated IRS-I was significantly changed in glucocorticoid-treated animals. Thus, there must have been an increase in the extent oftyrosine phosphorylation per mole of IRS-I in the presence of hypercortisolemia. In agreement with this phenomenon, Saad et al. have observed increased tyrosine phosphorylation of IRS-1, but decreased levels of the protein in the skeletal muscle of both fasted and STZ-diabetic animals (39) . It can be concluded that in vivo tyrosine phosphorylation ofIRS-I is regulated independent of changes in levels of the IRS-I protein.
The increase in phosphorylation per mole of IRS-I in glucocorticoid-treated animals contrasts with the decrease in tyrosine phosphorylation per mole of insulin receptor. A similar dissociation between changes in insulin receptor autophosphorylation and receptor kinase activity toward an artificial exogenous substrate has been described in insulin-resistant rat tissues (29, 40) and, in our recent work (26) , a lack of correlation between changes in tyrosine phosphorylation of insulin receptors and IRS-I was observed in the skeletal muscle of STZ-treated rats. It appears, therefore, that tyrosine phosphorylation of the insulin receptor and cellular substrates for the receptor can be independently regulated in vivo. These findings could be explained as a consequence of altered activity of specific phosphotyrosine phosphatases that, together with the receptor kinase, determine the level of tyrosine phosphorylation of IRS-I in the muscle cell.
Glucocorticoid treatment of rats resulted in a decrease in IRS-1 apparent Mr by 8-10 kD on SDS-PAGE. This cannot be attributed to proteolytic clipping, since the protein is recognized by both carboxy-terminal and amino-terminal peptide antibodies. It also is unlikely to result from a different extent of glycosylation of the protein, since IRS-1 is present in the cytosol (20) , and glycosylation of intracellular proteins has not been reported. Dephosphorylation of IRS-I from control muscle specifically at serine/threonine residues with PP-2AC resulted in a similar increase in electrophoretic mobility, whereas dephosphorylation had no effect on IRS-1 from glucocorti- In conclusion, the current study provides direct in vivo evidence that glucocorticoid-induced insulin resistance results in abnormalities in the intracellular signaling of insulin in skeletal muscle. The alterations are apparent at both receptor and postreceptor levels in the muscle cell. Insulin receptor tyrosine phosphorylation is decreased as a consequence of a decrease in the population of receptors capable of undergoing tyrosine phosphorylation. In addition, the expression of the endogenous insulin receptor substrate IRS-I is decreased and the levels of seine and/or threonine phosphorylation of this protein are reduced. In further studies, it will be important to investigate the pathophysiological significance of these alterations and, in particular, the impact of changes in the phosphorylation state of IRS-I on insulin action.
